Dynamics of the Gout Market: Addressing the Unmet Need for Improved Uric Acid Management and the Development of Novel Therapeutics for Chronic Disease Control
Gout, a painful and increasingly prevalent form of inflammatory arthritis caused by the deposition of uric acid crystals (monosodium urate) in the joints, is a growing chronic health concern, making the Gout Market a significant focus for pharmaceutical development. Market growth is primarily driven by the rising global prevalence of hyperuricemia, which is directly linked to adverse lifestyle factors such as high consumption of purine-rich foods and sugary drinks, high alcohol consumption, and increasing rates of obesity and metabolic syndrome globally. Current treatment strategies involve two main, critical phases: acute management of inflammatory flares using NSAIDs or colchicine, and chronic management aimed at consistently lowering serum uric acid (sUA) levels below saturation using urate-lowering therapies (ULTs) such as allopurinol and febuxostat. The significant unmet need lies…